Chromosome 13 Deletion/Hypodiploidy and Prognosis in Multiple Myeloma Patients

Reference

• Barlogie, B., Epstein, J., Selvanayagam, P. and Alexanian R. (1989) "Plasma cell myeloma — new biological insights and advances in therapy", Blood, 73, 865–879.
   PubMed Web of Science ®Google Scholar
• Kyle, R.A. (1994) "Why better prognostic factors for multiple myeloma are needed", Blood, 83, 1713— 1716.
   Google Scholar
• The Intergroupe Francais du Myelome, Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.-J., Fuzibet, J.-G., et al. (1996) "A prospective, randomized trial of autologous bone marrow trans-plantation and chemotherapy in multiple myeloma", New England Journal of Medicine, 335, 91 — 97.
   Google Scholar
• Barlogie, B., Jagannath, S., Vesole, D., Naucke, S., Cheson, B., Mattox, S., et al. (1997) "Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma", Blood, 89, 789 — 793.
   Google Scholar
• Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J.L., et al. (2000) "Impact on survival of high dose therapy with autologous stem cell supporting patients younger than 60 years with newly diagnosed multiple myeloma: a population based study", Blood, 95, 7–11.
   Google Scholar
• Child, J.A. Morgan, G.J., Davies, F.E., Owen, R.G., Bell, SE., Hawkins, K., et al. (2003) "High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma", New England Journal of Medicine, 348, 1875 — 1883.
   PubMed Web of Science ®Google Scholar
• Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., et al. (2002) "Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome", Blood, 100, 5a.
   Google Scholar
• Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., et al. (2000) "Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities", Blood, 95, 4008–4010.
   Google Scholar
• Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Ronconi, S., deVivo, A., et al. (2002) "The "Bologna 96" clinical trial of single vs. double transplant for previously untreated multiple myeloma patients", Blood, 100, 179a.
   Google Scholar
• Tricot, G., Spencer, T., Sawyer, J., Spoon, D., Desikan, R., Fassas, A., et al. (2002) "Predicting long-term ( 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplant", British Journal of Haematology, 116, 211 —217.
   Google Scholar
• Drach, J., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., et al. (1995) "Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridisation", Cancer Research, 55, 3854— 3859.
   Google Scholar
• Latreille, J., Barlogie, B., Johnston, D., Drewinko, B. and Alexanian R. (1982) "Ploidy and proliferative characteristics in monoclonal gammopathies", Blood, 59, 43–46.
   PubMed Web of Science ®Google Scholar
• Zandecki, M., Obein, V., Bernardi, F., Soenen, V., Flactif, M., Lai, J. L., et al. (1995) "Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells", British Journal of Haematology, 90, 693— 696.
   Google Scholar
• Drach, J., Angerler, J., Schuster, J., Rothermundt, C., Thalhammer, R., Haas, 0. A., et al. (1995) "Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance", Blood, 86, 3915— 3921.
   Google Scholar
• Fenaux, P., Preudhomme, C., Lai, J. L., Morel, P., Beuscart, R. and Bauters, F. (1989) "Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases", British Journal of Haematology, 73, 61–67.
   PubMed Web of Science ®Google Scholar
• Seeker-Walker, L.M. (1990) "Prognostic and biological importance of chromosome findings in acute lymphoblastic leukemia", Cancer Genetics Cytogenetics, 49, 1 — 13.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Sawyer, J. R., Jagannath, S., Desikan, R. K., Siegel, D., Naucke, S., et al. (1997) "Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants", Journal of Clinical Oncology, 15, 2659 — 2666.
   Google Scholar
• Shaughnessy J., Jacobson, J., Sawyer, J., McCoy, J., Fassas, A., Zhan, F., et al. (2003) "Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression", Blood, 101, 3849 — 3856.
   Google Scholar
• Seong, C., Delasalle, K., Hayes, K., Weber, D., Dimopoulos, M., Swantkowski, J., et al. (1998) Prognostic value of cytogenetics in multiple myeloma. British Journal of Haematology, 101, 189–194.
   PubMed Web of Science ®Google Scholar
• Weh, H.J., Gutensohn, K., Selbach, J., Kruse, R., Wacker-Back-haus, G., Seeger, D., et al. (1993) "Karyotype in multiple myeloma and plasma cell leukemia", European Journal of Cancer, 29A, 1269 — 1273.
   Google Scholar
• La, J.L., Zandecki, M., Mary, J.Y., Bernardl, P., Izydorczyk, V., Flactif, M., et al. (1995) "Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis", Blood, 85, 2490–2497.
   Google Scholar
• Smadja, N.-V., Fruchart, C., Isnard, F., Louvet, C., Dutel, J.-L., Cheron, N., et al. (1998) "Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases", Leukemia, 12, 960–969.
   Google Scholar
• Fassas, A.B.-T., van Rhee, F. and Tricot, G. (2003) "Predicting long-term survival in multiple myeloma patients following auto-transplant", Leukemia and Lymphoma, 44, 749 — 758.
   Web of Science ®Google Scholar
• Intergroupe Francophone du Myelome Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.-L., et al. (2002) "Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive che-motherapy", Blood, 100, 1579— 1583.
   Google Scholar
• Shaughnessy J. Jr., Tian, E., Sawyer, J., McCoy, J., Tricot, G., Jacobson, J., et al. (2003) "Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II", British Journal of Haematology, 00, 44— 52.
   Google Scholar
• Gahrton, G., Svensson, H, Cavo, M., Apperly, J., Bacigalupo, A., Bjorkstrand, B., et al. (2001) "Progress in allogenic bone marrow and peripheral stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centers", British Journal of Haematology, 113, 209–216.
   Google Scholar
• Heerema, N.A., Nachman, J.B., Sather, H.N., Sensel, M.G., Lee, M.K., Hutchinson, R., et al. (1999) "Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group", Blood, 94, 4036–4404.
   Google Scholar
• Pujol, J.L., Simony, J., Jolimony, G., Jaffuel, D., Demoly, P., Quantin, X., et al. (1996) "Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers", British Journal of Cancer, 74, 964–970.
   PubMed Web of Science ®Google Scholar
• Rubio Bueno, P., Navel Gias, L., Garcia Delgado, R., Domingo Cebollada, J. and Diaz Gonzalez, F.J. (1998) "Tumor DNA content as prognostic indicator in squamous cell carcinoma of the oral cavity and tongue base", Head and Neck, 20, 232–239.
   Google Scholar
• Perez Simon, J.A., Garcia-Sanz, R., Tabernero, M.D., Almeida, J., Gonzalez, M., Fernández-Calvo, J., Moro, M. J., Hernández, J. M., San Miguel, J. P., and Odd°, A. (1998) "Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes", Blood, 91, 3366— 3371.
   Google Scholar
• Latreille, J., Barlogie, B., Dosik, G., Johnston, D.A., Drewinko, B. and Alexanian, R. (1980) "Cellular contents as a marker of human multiple myeloma", Blood, 55, 403–408.
   Google Scholar
• Tafuri, A., Meyers, J., Lee, B.J. and Andreeff, M. (1991) "DNA and RNA flow cytometric study in multiple myeloma: clinical correla-tions", Cancer, 67, 449 — 454.
   Google Scholar
• Barlogie, B., Alexanian, R., Dixon, D., Smith, L., Smallwood, L. and Delasalle, K. (1985) "Prognostic implications of tumor cell DNA and RNA content in multiple myeloma", Blood, 66, 338 — 341.
   Google Scholar
• Garcia-Sanz, R., Ortao, A., Gonzalez, M., Moro, M. J., Hernandez, M., Ortega, P., et al. (1995) "Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients", British Journal of Haematology, 90, 106 — 112.
   Google Scholar
• Greipp, P.R., Trendle, M.C., Leong, T., Oken, M.M., Kay, N.E., Van Ness, B., and Kyle, R.A. (1999) "Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?", Leukemia and Lymphoma, 35, 83–89.
   Web of Science ®Google Scholar
• Calasanz, M.J., Cigudosa, J.C., Odero, M.D., Garcia-Poncillas, J., Main, J., Ardanaz, MT., et al. (1997) "Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma", British Journal of Haematology, 98, 418–425.
   PubMed Web of Science ®Google Scholar
• Smadja, N.-V., Bastard, C., Brigaudeau, C., Leroux, D. and Fruchart, C. (2001) "Hypodiploidy is a major prognostic factor in multiple myeloma", Blood, 98, 2229 — 2238.
   Google Scholar
• Dewald, G., Kyle, R.A., Hicks, G.A. and Greipp, P.R. (1985) "The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis", Blood, 66, 380— 390.
   Google Scholar
• Sawyer, J.R., Waldron, J.A., Jagannath, S. and Barlogie, B. (1995) "Cytogenetic findings in 200 patients with multiple myeloma", Cancer Genetics and Cytogenetics, 82, 41 — 49.
   Google Scholar
• Fassas, A.B.-T., Spencer, T., Sawyer, J., Zangari, M. Lee, C.-K., Anaissie, E., Muwalla, F., et al. (2002) "Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma", British Journal of Haematology, 118, 1041 — 1047.
   Google Scholar
• Jacobson, J., Barlogie, B., Shaughnessy, J., Drach, J., Tricot, G., Fassas, A., et al. (2003) "MDS-type abnormalities within myeloma signature karotype (MM-MDS): only 13% 1-year survival despite tandem transplants", British Journal of Haematology, 122, 430–440.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., et al. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identi-fication of prognostic factors in a phase 2 study of 169 patients", Blood, 98, 492–494.
   Google Scholar
• Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., et al. (2003) "Treatment in Multiple Myeloma", Blood (in press).
   Google Scholar
• Tricot, G., Vesole, D., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996) "Graft-versus-myeloma effect: proof of princi-ple", Blood, 87, 1196–1198.
   Google Scholar
• Bensinger, W. I., Buckner, C. D., Anasetti, C. Clift, R., Storb, R., Barnett, T., et al. (1996) "Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome", Blood, 88, 2787 — 2793. f461 Bjorkstrand B.B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Apperley, J., et al. (1996) "Allogeneic bone marrow transplanta-tion versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation", Blood, 88, 4711 — 4718.
   Google Scholar
• Maloney, D.G., Molina, A.J., Sahebi, F., Stockerl-Goldstein, K.E., Sandmaier, B.M., Bensinger, W., et al. (2003) "Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma", Blood, 102, 3447 — 3454.
   Google Scholar
• Lee, C.-K., Badros, A., Barlogie, B., Morris, C., Zangari, M., Fassas, A., et al. (2003) "Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning", Experimental Hematology, 31, 73 — 80.
   Google Scholar
• Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. (2003) "A phase 2 study of Bortezomib in relapsed, refractory myeloma", New England Journal of Medicine, 348, 2609 — 2617.
   Google Scholar
• Richardson, P.G.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. (2003) "Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma (MM) treated with Bortezomib", Meeting Proceedings of the American Society of Clinical Oncology, 22, 581.
   Google Scholar
• Zavrski, I, Naujokat, C., Niemoller, K., Jakob, C., Heider, U., Langelotz, C., et al. (2003) "Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cells irrespective of chromo-somel 3 deletion", Journal of Cancer Research Clinical Oncology, 129, 383–391.
   PubMed Web of Science ®Google Scholar